Standard Nivolumab Dosing in Adults
Nivolumab (Opdivo) is typically dosed at 3 mg/kg intravenously every 2 weeks for most approved indications in adults, such as melanoma, non-small cell lung cancer, and renal cell carcinoma.[1] This flat mg/kg regimen applies to patients regardless of body weight above typical adult ranges, with adjustments for specific combinations or tumors.
Dosing for Combination Therapy
When combined with ipilimumab, the dose drops to 1 mg/kg every 3 weeks for the first 4 doses, followed by 3 mg/kg nivolumab every 2 weeks.[1] For nivolumab plus chemotherapy in NSCLC or gastric cancer, it remains 360 mg flat dose every 3 weeks (not weight-based).[1]
Weight-Based vs. Flat Dosing Shift
Early regimens used strict mg/kg (e.g., 3 mg/kg Q2W), but FDA approvals since 2021 allow fixed doses like 240 mg every 2 weeks or 480 mg every 4 weeks for many monotherapy uses, calibrated to approximate 2-3 mg/kg for a 70-80 kg adult.[1][2] Flat dosing simplifies administration but caps at lower effective rates for patients over 100 kg.
How Dosing Is Calculated in Practice
Clinicians calculate mg/kg using actual body weight (ABW) unless obese, where ideal body weight (IBW) or adjusted body weight may be used to avoid overdose.[2] Infusion occurs over 30 minutes; no loading dose is standard. Pediatric dosing differs (0.3 mg/kg for some indications).[1]
Dose Adjustments and Limits
Reduce to 240 mg or 480 mg flat if grade 3+ immune-related toxicity occurs, with holds or discontinuation per protocol.[1] No routine adjustments for renal/hepatic impairment, but monitor closely. Maximum single dose isn't formally capped in mg/kg regimens, though flat-dose approvals imply ~6 mg/kg upper limit for heavy patients.[2]
[1]: Opdivo (nivolumab) Prescribing Information
[2]: DrugPatentWatch.com - Nivolumab Patents and Dosing